AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia from chronic kidney disease (CKD), after supportive phase 3 results.
AstraZeneca has announced three research initiatives in China including a potential $1 billion investment fund, in a country described by CEO Pascal Soriot as a “scientific powerhouse”.
Big-selling drugs often spark legal bunfights as companies squabble over who did what during the development process and what share of profits they deserve – and Daiichi Sankyo and AstraZen
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
